cemiplimab
regeneron,sanofi
['lcsm,(-blcsm)', 'cemiplimab', 'lung', 'empower-lung1']
in the #lcsm session we were told that cemiplimab is a soc in pts with &gt;50% pd-l1 expression (empower-lung1). i disagree. how can a treatment being tested in a study population containing 12% females be a soc in 2022? why is this even approved by #fda and #ema?
#esmo2022
I am physician and researcher passionate about advancing precision oncology and lung cancer treatments. Views are my own.